Format

Send to

Choose Destination
J Diabetes Sci Technol. 2014 Sep;8(5):1005-10. doi: 10.1177/1932296814537040. Epub 2014 May 27.

Cross-sectional survey and retrospective analysis of a large cohort of adults with type 1 diabetes with long-term continuous subcutaneous insulin infusion treatment.

Author information

1
Endocrinology Department, Caen University Hospital, Caen, France joubert-m@chu-caen.fr.
2
Endocrinology Department, Caen University Hospital, Caen, France University of Caen (UNICAEN), Caen, France.
3
Endocrinology Department, Caen University Hospital, Caen, France.
4
University of Caen (UNICAEN), Caen, France Research and Biostatistic Department, Caen University Hospital, Caen, France.

Abstract

BACKGROUND:

Continuous subcutaneous insulin infusion (CSII) is an established modality for intensive insulin treatment of type 1 diabetes (T1D), but long-term data concerning satisfaction, CSII function use, safety, and efficacy in real-life conditions are scarce.

METHODS:

We analyzed a cohort of adult patients with T1D treated with CSII for more than 1 year in a single diabetes center. We performed a cross-sectional survey in 2010 (tolerance/satisfaction and behavior forms) and a retrospective analysis of medical records (including HbA1c level, hospitalization, and catheter infections). The primary objective was to assess long-term tolerance/satisfaction, and secondary objectives were safety and efficacy.

RESULTS:

There were 295 patients analyzed. After a median duration of CSII use of 5 years, overall satisfaction was high for about 90% of patients. Mean CSII-related discomfort scores were low for work, recreation, and sleep and moderate for sport and sexual activity (2.5 ± 1.9, 2.6 ± 1.8, 2.6 ± 2.1, 3.4 ± 2.3, and 4.0 ± 2.9 of 10, respectively). Despite a high level of diabetes education, only one third of patients were using advanced CSII functions. During long-term follow-up, the safety of CSII treatment was good; the hospitalization rate was 0.18 patients/year, and catheter infections were scarce. The HbA1c level dropped about -0.5% independently from CSII duration (P < .05).

CONCLUSIONS:

In this adult cohort, satisfaction and tolerance, together with safety, of CSII were maintained at long-term follow up. The sole basic functions of CSII were currently used by patients. A 0.5% decrease in the HbA1c level was maintained during the study period.

KEYWORDS:

HbA1c; continuous subcutaneous insulin infusion; insulin; quality of life; type 1 diabetes

PMID:
24876454
PMCID:
PMC4455364
DOI:
10.1177/1932296814537040
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center